[
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).Discussion\nWe evaluated the associations of the most recently developed breast and prostate cancer PRS with site-specific cancer risks in the largest case-control study of male BRCA1 and BRCA2 carriers available to date.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ (PLRT ≥ .61) or PRSPC (PLRT = .52) associations differed by the pathogenic variant location in the gene (Table 3).Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSER+ associations differed by country (Pheterogeneity ≥ .48; Supplementary Figure 3, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "There was no statistically significant evidence that the PRSPC associations differed by country (Pheterogeneity ≥ .14; Supplementary Figure 4, available online).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Absolute Risks of Developing Breast and Prostate Cancer\nThe absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores; PRSER+ = ER-positive breast cancer PRS.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "PRS = polygenic risk scores PRSER+ = ER-positive breast cancer PRS.The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The absolute risks of developing breast cancer by age 85 years for BRCA2 carriers was predicted to be 7.7% at the 5th and 18.4% at the 95th PRSER+ distribution percentiles (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The 10-year risks of developing breast cancer at 50 years were 0.8% at the 5th and 2.0% at the 95th PRSER+ distribution percentiles for BRCA2 carriers (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ten-year risks were calculated from the absolute risks of developing breast cancer or prostate cancer (Figure 1). (A) The 10-year risks of developing breast cancer for BRCA2 carriers by PRSER+ percentiles. (B) The 10-year risks of developing prostate cancer for BRCA1 pathogenic variant carriers by PRSPC percentiles. (C) The 10-year risks of developing prostate cancer for BRCA2 pathogenic variant carriers by PRSPC percentiles.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The predicted absolute risks of developing prostate cancer by age 85 years were 13.1% at the 5th and 50.4% at the 95th PRSPC distribution percentiles for BRCA1 carriers (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The corresponding risks at age 75 years were 25.5% and 77.0% (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]